April 22, 2026 – The Week in Health Care News

Key Takeaways

• Ohio Supreme Court may permit new anti‑abortion statutes despite voter approval
• Pennsylvania court restores Medicaid coverage for abortions, citing constitutional right
• DOJ dismissed prosecutors over alleged bias favoring anti‑abortion activists
• Sen. Wyden challenges EPA's water‑safety list targeting contraceptives and abortion drugs
• Study estimates $7.8 billion loss over five years from falling measles vaccination

Pulse Analysis

State‑level fights over abortion rights are intensifying as courts and legislatures clash over voter‑mandated protections. In Ohio, a conservative supreme court could still endorse restrictive statutes, while Arizona and Idaho see similar legislative pushes and ballot initiatives. These legal maneuvers not only threaten access for women but also set precedents that could ripple nationwide, influencing future ballot measures and shaping the political calculus for upcoming elections.

At the federal level, the Justice Department’s recent dismissal of prosecutors accused of bias toward anti‑abortion groups signals heightened scrutiny of partisan enforcement. Simultaneously, Sen. Ron Wyden’s challenge to the EPA’s new water‑safety list—targeting contraceptives and abortion‑inducing drugs—highlights how environmental policy is being leveraged in cultural wars. The Trump‑era health agenda is under fire as Senate‑released data reveal that drug‑price agreements have produced an average $353,000 annual price tag for new medications, contradicting the administration’s affordability narrative. The nomination of former deputy surgeon general Erica Schwartz to lead the CDC marks a potential shift away from vaccine skepticism, yet her tenure will be closely watched amid ongoing debates over public‑health leadership.

Beyond policy, the public‑health impact is stark. RFK Jr.’s recent hearings show a tentative embrace of the measles vaccine, yet his earlier anti‑vaccine rhetoric coincides with a surge to over 2,000 measles cases, prompting a Bloomberg‑cited $7.8 billion projected cost over five years. Rural health funding remains ineffective, exemplified by the closure of a Nebraska dialysis unit despite a $219 million state investment. Together, these stories illustrate how political battles, funding gaps, and misinformation converge to threaten both health outcomes and economic stability across the United States.